The University of Colorado Cancer Center (UCCC) is the only NCI-designated comprehensive Cancer Center in Colorado serving a primary catchment area of Colorado and Wyoming with a population of ~5.5M. During the past five years, peer-reviewed cancer-related funding reached $102M and 3,181 publications (35% collaborative) were produced. Outpatient visits and clinically active faculty are growing, which will translate into a ranked increase in patient accruals to clinical trials. UCCC is an NCI-recognized consortium encompassing Univ. of Colorado Boulder, Colorado State University, National Jewish Health, Univ. of Colorado Hospital (UCH), the Colorado Children's Hospital, Denver Health System, Kaiser Permanente of Colorado and the Denver Veterans Administration Medical Center. We also have a growing number of outreach clinics staffed directly by our faculty including Montrose Hospital in Montrose, Valley View Hospital in Glenwood Springs, and Vail Valley Medical Center in Edwards. Our affiliates (CGOPs) include St. Mary's in Grand Junction. UCH has constructed a new outpatient tower for oncology care (opened May 2012), and is nearing completion of a new inpatient tower (March 2013). UCH has merged with our former affiliates, Poudre Valley Medical Center (PVMH) in Ft. Collins and Memorial Hospital (MH) in Colorado Springs, under the unified University of Colorado Health Systems. The cancer components of these two hospital systems will formally join the UCCC consortium later this year. The LAPS U10-funded membership in the NCTN and in SWOG and NRG fulfills many of the goals of our Cancer Center by providing broad access to innovative Phases II and III treatment and chemoprevention trials to the citizens of Colorado. This grant provides partial support for the monitoring and oversight to run clinical trials at the main institutions. Our faculties have provided strong administrative and scientific leadership, throughout the NCTN, by serving or chairing SWOG and RTOG committees, serving as PIs for Phases ll/lll SWOG, GOG, ACOSOG, RTOG, and NSABP group trials including PLCO, PCPT, SELECT and NLST/ACRIN. Clinical trials represent the state-of-the-art in cancer treatment and prevention and should be broadly available and offered to the citizens of Colorado.

Public Health Relevance

As the only NCI-designated Cancer Center in the State of Colorado, the UCCC innovates in the development of more effective approaches to prevention, diagnosis, and therapy of cancer. Clinical trials, especially Phase III studies, drive progress and establish new standards of care (SOC). This grant provides essential resources to support these clinical trials to our Cancer Center and to multiple sites around the Rocky Mountain region. Access to clinical trials is crucial for excellence in health care.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Murtola, Teemu J; Gurel, Bora; Umbehr, Martin et al. (2016) Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 25:463-9
Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7
Cooper, Todd M; Cassar, Jeannette; Eckroth, Elena et al. (2016) A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res 22:4014-22
Myers, Andrea P; Filiaci, Virginia L; Zhang, Yuping et al. (2016) Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 141:43-8
Al-Hallaq, Hania A; Chmura, Steven; Salama, Joseph K et al. (2016) Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. Pract Radiat Oncol 6:e291-e298
Xiao, Canhua; Zhang, Qiang; Nguyen-Tân, Phuc Felix et al. (2016) Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 012 Int J Radiat Oncol Biol Phys :
Kulac, Ibrahim; Gumuskaya, Berrak; Drake, Charles G et al. (2016) Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial . Prostate 76:1399-408
Lara Jr, Primo N; Moon, James; Hesketh, Paul J et al. (2016) SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol 11:420-5
White, Julia; Winter, Kathryn; Kuske, Robert R et al. (2016) Long-Term Cancer Outcomes From Study NRG Oncology/RTOG 9517: A Phase 2 Study of Accelerated Partial Breast Irradiation With Multicatheter Brachytherapy After Lumpectomy for Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys 95:1460-5
Divi, Vasu; Harris, Jonathan; Harari, Paul M et al. (2016) Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer :

Showing the most recent 10 out of 35 publications